MOLOGEN AG
MOLOGEN AG: Presentation of DNA vaccine against leishmaniasis at IMED 2014
MOLOGEN AG / Key word(s): Study results MOLOGEN AG: Presentation of DNA vaccine against leishmaniasis at IMED 2014 Berlin, November 3, 2014 – The LEISHDNAVAX consortium, with the biotechnology company MOLOGEN AG as a key partner, presented preclinical data of the leishmaniasis vaccine (MGN1331) in a poster at the International Meeting on Emerging Diseases and Surveillance (IMED) in Vienna. Data on the immunogenicity and prophylactic efficacy of the DNA-based leishmaniasis vaccine was shown. Leishmaniasis is a neglected tropical disease that severely affects large populations worldwide. A vaccine is needed to prevent, control and eliminate leishmaniasis in endemic regions. The abstract and more information on LEISHDNAVAX (MGN1331) can be found on: http://imed.isid.org/. Abstract details: About leishmaniasis About MGN1331 In the field of biotechnology, transport vehicles for conveying nucleic acids (mostly DNA) are called vectors. The MIDGE(R) technology developed by MOLOGEN (MIDGE(R) stands for Minimalistic Immunologically Defined Gene Expression) is also termed a DNA vector. However, unlike other DNA vectors (plasmids, viruses), the MIDGE(R) vector contains only the information necessary for the actual effect. Its minimalistic design ensures avoidance of undesirable components often found in conventional vectors. MIDGE(R) vectors form the basis for a broad spectrum of modern, DNA-based applications. These vectors are designed with various characteristics that are partly individualized and are exceptionally well-suited for both gene therapy for cancer and DNA-based vaccination against infectious diseases. Members of the LEISHDNAVAX consortium: – London School of Hygiene & Tropical Medicine (LSHTM) – Charité – Universitätsmedizin Berlin (Charite) – Indian Institute of Chemical Biology (IICB), Kolkata – Institut Pasteur de Tunis (IPT) – Hebrew University of Jerusalem (HUJI) – Rajendra Memorial Research Institute of Medical Sciences (RMRI-MS) – Drugs for Neglected Diseases Initiative (DNDi) – MOLOGEN AG About MOLOGEN AG The cancer immune therapy MGN1703 is the company’s lead product and best-in-class TLR-9 agonist. It is currently developed for first-line maintenance treatment of colorectal cancer (pivotal randomized trial) and lung cancer (randomized controlled trial). A second clinical-stage product is MGN1601, a therapeutic vaccination for the treatment of renal cancer. A phase I/II clinical study has already been completed successfully. With unique, patented technologies and innovative products, MOLOGEN is pioneering immune therapies. MOLOGEN AG is a publicly listed company, headquartered in Berlin. The shares (ISIN DE0006637200) are listed in the Prime Standard of the German Stock Exchange. www.mologen.com Memberships in associations: MIDGE(R), dSLIM(R), EnanDIM(R) and MOLOGEN(R) are registered trademarks of MOLOGEN AG. MOLOGEN AG Claudia Nickolaus Note about risk for future predictions
03.11.2014 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de |
Language: | English | |
Company: | MOLOGEN AG | |
Fabeckstraße 30 | ||
14195 Berlin | ||
Germany | ||
Phone: | 030 / 841788-0 | |
Fax: | 030 / 841788-50 | |
E-mail: | info@mologen.com | |
Internet: | www.mologen.com | |
ISIN: | DE0006637200 | |
WKN: | 663720 | |
Listed: | Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, München, Stuttgart | |
End of News | DGAP News-Service |
294568 03.11.2014 |